Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06284564
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-02-21
Brief Title:
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma BOOST-RCC
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2023-0538
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| United States Department of Defense | FED |
| Bristol-Myers Squibb | INDUSTRY |
| Cancer Prevention Research Institute of Texas | OTHER |